Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients
Recruiting · NCT06991712 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The goal of this clinical trial is to determine whether oral supplementation with different nicotinamide adenine dinucleotide (NAD) precursors can improve visual function in adults with primary open-angle glaucoma. The main questions it aims to answer are: 1. Does daily oral administration of equimolar doses of nicotinamide riboside (NR), nicotinamide (NAM), nicotinamide mononucleotide (NMN), or nicotinic acid (NA) improve visual field sensitivity in glaucoma patients over the short term? 2. How do plasma NAD+ metabolite profiles change after administration of each precursor, and do these changes relate to improvements in visual function? Researchers will compare NR, NAM, NMN, NA, and placebo groups to see if any of the NAD precursors lead to greater improvements in visual field sensitivity or changes in blood NAD+ metabolite levels compared to placebo. Participants will: Be randomly assigned to receive one of the four NAD precursors or placebo daily for two weeks. Undergo comprehensive eye examinations, including visual field testing and optical coherence tomography, at baseline and after two weeks. Provide blood samples before and after the intervention for measurement of NAD+ metabolites. Have safety monitored through clinical examination. This study will help identify whether boosting NAD+ levels with specific precursors offers functional benefit in glaucoma, and which blood metabolites may mediate these effects.
Who can take part
Inclusion criteria
- glaucoma patients
- age ≥ 18 years
- best corrected VA ≥20/40
- IOP \<21 mmHg
- visual field mean deviation better than -24 dB on standard automated perimetry 24-2 SITA standard
Exclusion criteria
- pathological myopia
- diseases that may cause visual field loss or optic disc abnormalities other than glaucoma
- inability to perform reliable visual field
- suboptimal quality of OCT images
- diabetic retinopathy/maculopathy
- history of abnormal liver function within 12 months
- known allergy to NAD precursor supplement(s)
- pregnancy or lactation
- use of NAD precursor supplements 14 days prior to baseline.
Where it is running
1 location listed.
- HKU Eye Centre - Wong Chuk Hang, Hong Kong